인도의 체외수정(IVF) 기기 시장 평가 : 제품 유형별, 시술 유형별, 최종 사용자별, 지역별, 기회 및 예측(2018-2032년)

India in-vitro fertilization instruments market is projected to witness a CAGR of 7.70% during the forecast period FY2025-FY2032F, growing from USD 1.13 billion in FY2024 to USD 2.05 billion in FY2032.

The in-vitro fertilization instruments market in India has grown significantly because of recent advancements in IVF techniques and the growing demand for efficient solutions. One of the primary factors propelling market expansions in the country is most of the population's declining reproductive health due to sedentary lifestyles and shifting environmental conditions. The taboo still associated with it is gradually dissolving and people are more freely availing these medical options as awareness spreads countrywide. Furthermore, government investments in healthcare infrastructure, technological advancements, and the growing demand for cutting-edge solutions reinforce the market's growth trajectory. Rapid advancements in healthcare, particularly in Asia-Pacific, present lucrative prospects. For example, the Sabine Hospital, an IVF hospital based in Kerala, announced in February 2024 that it was all set to install its new and advanced machine to identify genetic diseases while the fetus was still in the womb. This machine, known as the Next Generation Sequencer (NGS), is used to detect genetic diseases in the developing fetus.

Rising Acceptance and Awareness about In-Vitro Fertilization (IVF) Boosts Market Growth

The expansion of India's fertility business has been greatly aided by the increasing awareness and public acceptance of in-vitro fertilization (IVF). Infertility was once a taboo topic, but because of healthcare initiatives, media influence, and education, there is now more openness and acceptance of IVF procedures.

Due to better access to information through digital platforms and healthcare campaigns, couples who have trouble conceiving are now more likely to look for medical options. Furthermore, IVF is now more widely available due to the growth of fertility clinics in Tier 2 and Tier 3 cities, affordable treatment choices, and government initiatives. The industry has grown on the backdrop of shifting attitudes, the acceptance of IVF among LGBTQ+ people and single parents, and corporate insurance coverage for fertility treatments.

For instance, Nova IVF introduced "Fertility Tales," a podcast project in November 2023, to raise awareness about fertility treatment through engaging narratives. The podcast interviews industry stakeholders and shares real patient stories about firsthand experiences with IVF treatment.

Rising Infertility Rate Accelerates India In-Vitro Fertilization (IVF) Instruments Market Growth

The need for in-vitro fertilization (IVF) is being greatly increased by the steep increase in infertility rates in India. The main causes of infertility in both men and women are changing lifestyles, stress, late marriages, obesity, pollution, and rising health disorders such as diabetes and PCOS. Infertility problems affect approximately 10-15% of Indian couples, with a higher prevalence in metropolitan areas, according to the Indian Society of Assisted Reproduction (ISAR).

The spike in infertility cases has spurred the growth of IVF clinics and fertility centres across India. Couples are now more inclined to pursue IVF treatments due to rising awareness, affordability, and technological advancements including AI-driven embryo selection and enhanced cryopreservation techniques. Fertility treatments are also becoming more widely available in India due to initiatives taken by our government and the country's expanding medical tourism.

As infertility cases continue to rise, the Indian IVF market is expected to witness exponential growth in the coming years. For instance, the government of Goa launched the Intrauterine Insemination /In Vitro Fertilization and Assisted Reproductive Technology Centre in August 2023 at the Goa Medical College and Hospital (GMC); providing infertility treatment free of cost.

Rising Infrastructure Fuels the India In-Vitro Fertilization (IVF) Instruments Market Growth

India's in-vitro fertilization (IVF) market has grown tremendously because of the nation's rapidly developing healthcare infrastructure. Fertility treatments are now more widely accessible due to the construction of specialized fertility centers, cutting-edge reproductive laboratories, and enhanced hospital facilities throughout metropolitan and semi-urban areas. Prominent healthcare organizations such as Apollo, Fortis, and Nova IVF Fertility have extended their IVF offerings by incorporating state-of-the-art technology such as genetic testing, sophisticated cryopreservation, and AI-based embryo selection. Infrastructure development is accelerated by government efforts such as Public-Private Partnerships (PPP) and greater foreign investments. Furthermore, the growth of medical tourism has drawn people from all over the world due to India's high-quality fertility therapies and affordability. IVF adoption is also fueled by improved healthcare accessibility and connection in tier-2 and tier-3 cities. With continuous investments in healthcare infrastructure and innovation, India's IVF market is set for exponential growth, catering to rising infertility rates and evolving patient needs.

For instance, in January 2024, CK Birla Healthcare Pvt. Ltd. introduced a new fertility clinic in Meerut, Uttar Pradesh that caters to various fertility issues in people.

Future Market Scenario (FY2025 - FY2032F)

Many factors contribute to the growth of India In-vitro fertilization instruments market. Technological advancements give faster and more accurate results leading us to early diagnosis. Opportunity also lies in the increasing fertility concerns the population faces today. Promising initiatives of our government that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial.

For instance, in December 2023, Little Angel IVF launched in vitro fertilization treatments such as personalized fertility consultation, comprehensive diagnostic services, advanced IVF treatments, and intracytoplasmic sperm injection (ICSI) for Non-Resident Indian patients.

Key Players Landscape and Outlook

Key players in India's in-vitro fertilization industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, in December 2023, Progenesis IVF Private Limited, a renowned genetic testing brand, expanded its operations to India by launching its first genetic laboratory in New Delhi.

In March 2023, Santaan Fertility Center & Research Institute Private Limited launched a new fertility clinic and research institute in the state of Odisha, India and Indira IVF opened its 116th IVF center in Pune, Maharashtra, an addition to the existing center in Pune.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India In-Vitro Fertilization Instruments Market Outlook, FY2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product Type
    • 4.2.1.1. Equipment
      • 4.2.1.1.1. Incubators
      • 4.2.1.1.2. Cryosystem
      • 4.2.1.1.3. Imaging Systems
      • 4.2.1.1.4. Ovum Aspiration Pumps
      • 4.2.1.1.5. Micromanipulators
      • 4.2.1.1.6. Sperm Separation Systems
      • 4.2.1.1.7. Others
    • 4.2.1.2. Reagents and Media
      • 4.2.1.2.1. Embryo Culture Media
      • 4.2.1.2.2. Cryopreservation Media
      • 4.2.1.2.3. Sperm Processing Media
      • 4.2.1.2.4. Others
    • 4.2.1.3. Software and Services
  • 4.2.2. By Procedure Type
    • 4.2.2.1. Fresh Donor IVF
    • 4.2.2.2. Fresh Non-Donor IVF
    • 4.2.2.3. Frozen Donor IVF
    • 4.2.2.4. Frozen Non-Donor IVF
    • 4.2.2.5. Natural Cycle IVF
    • 4.2.2.6. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Fertility Clinics
    • 4.2.3.2. Hospitals
    • 4.2.3.3. Research Institutes and Academic Centers
    • 4.2.3.4. Cryobanks
  • 4.2.4. By Region
    • 4.2.4.1. North
    • 4.2.4.2. South
    • 4.2.4.3. East
    • 4.2.4.4. West & Central
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Product Type
  • 4.3.2. By Procedure Type
  • 4.3.3. By End-user
  • 4.3.4. By Region

All segments will be provided for all regions and countries covered

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials
• 13.2. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. CK Birla Healthcare Pvt. Ltd.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. STECH IVF Solutions Private Limited
  • 16.3.3. ShineLife Meditec LLP
  • 16.3.4. Shivani Scientific Industries (P) Ltd.
  • 16.3.5. Navdurga Scientific Pvt. Ltd.
  • 16.3.6. Vardhman Medicare Pvt. Ltd.
  • 16.3.7. SAR Healthline Private Limited
  • 16.3.8. Amensco Medical Technologies Pvt. Ltd.
  • 16.3.9. Esco Lifesciences Group
  • 16.3.10. IMV Technologies Group (Cryo Bio System)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer